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Abstract
BAF (Barrier to Autointegration Factor) is a highly conserved DNA binding protein that senses poxviral DNA in the cytoplasm
and tightly binds to the viral genome to interfere with DNA replication and transcription. To counteract BAF, a poxviral-
encoded protein kinase phosphorylates BAF, which renders BAF unable to bind DNA and allows efficient viral replication to
occur. Herein, we examined how BAF phosphorylation is affected by herpes simplex virus type 1 (HSV-1) infection and
tested the ability of BAF to interfere with HSV-1 productive infection. Interestingly, we found that BAF phosphorylation
decreases markedly following HSV-1 infection. To determine whether dephosphorylated BAF impacts HSV-1 productive
infection, we employed cell lines stably expressing a constitutively unphosphorylated form of BAF (BAF-MAAAQ) and cells
overexpressing wild type (wt) BAF for comparison. Although HSV-1 production in cells overexpressing wtBAF was similar to
that in cells expressing no additional BAF, viral growth was reduced approximately 80% in the presence of BAF-MAAAQ.
Experiments were also performed to determine the mechanism of the antiviral activity of BAF with the following results.
BAF-MAAAQ was localized to the nucleus, whereas wtBAF was dispersed throughout cells prior to infection. Following
infection, wtBAF becomes dephosphorylated and relocalized to the nucleus. Additionally, BAF was associated with the HSV-
1 genome during infection, with BAF-MAAAQ associated to a greater extent than wtBAF. Importantly, unphosphorylated
BAF inhibited both viral DNA replication and gene expression. For example, expression of two regulatory proteins, ICP0 and
VP16, were substantially reduced in cells expressing BAF-MAAAQ. However, other viral genes were not dramatically affected
suggesting that expression of certain viral genes can be differentially regulated by unphosphorylated BAF. Collectively,
these results suggest that BAF can act in a phosphorylation-regulated manner to impair HSV-1 transcription and/or DNA
replication, which is similar to the antiviral activity of BAF during vaccinia infection.
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Introduction
Herpes simplex virus type 1 (HSV-1) is a common human
pathogen; approximately 60% of the U.S. population is infected
and even greater rates of infection are estimated worldwide [1–3].
Recurrent ocular HSV-1 infection is a leading cause of infectious
corneal blindness in industrialized nations [4–6] and HSV-1
induced encephalitis (HSE) is a severe form of focal necrotizing
encephalitis that affects at least 2,000 individuals each year in the
U.S.[7–9]. HSV gene expression in productively infected cells is
temporally regulated in three distinct phases: immediate early (IE),
early (E), or late (L) [10]. IE transcription does not require protein
synthesis and is stimulated by a viral tegument protein, VP16 [11].
E gene expression is dependent on at least one IE protein, and
generally E genes encode nonstructural proteins that play a role in
viral DNA synthesis. L gene expression is maximal after viral DNA
replication, requires IE protein production, and L proteins
comprise the virion particle.
Specific functions involving regulation of gene expression and
interaction with host restriction factors have been ascribed to
many viral proteins present early in the infection. For example,
four IE genes encode ICP0, ICP4, ICP22, and ICP27. ICP4 [12–
14] and ICP27 [15–17] are required for efficient virus growth in
tissue culture. In general, ICP4 represses IE gene expression
[13,18–22] but activates E or L gene expression by interacting
with RNA polymerase II transcription factors [19,23]. ICP27
redistributes small nuclear ribonucleoprotein complexes, interferes
with splicing of IE transcripts, and promotes E and L poly-A site
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selection [24,25]. ICP0 can activate expression of all classes of viral
genes, in part because it increases steady-state levels of mRNA
[26]. ICP0 also binds several cellular proteins: 1) elongation factor
1d [27], 2) cyclin D3 [28], 3) an ubiquitin-specific protease
[29,30], and 4) PML [31–33]. Interactions between ICP0 and
chromatin-remodeling enzymes activate viral transcription [34–
38]. Secondly, ICP0 alters a complex that inhibits gene expression
(REST/CoREST/histone deacetylase repressor complex) [35]. In
addition to these proteins, HSV-1 encodes several other factors
that interfere with antiviral responses, thus promoting productive
infection [39–41]. The complex interactions that occur between
HSV-1 and host factors, including innate and intrinsic immune
regulators, determine the outcome of an infection.
Barrier-to-autointegration factor (BAF/BANF1) is an essential,
highly conserved metazoan protein with multiple functions linked
to maintaining the integrity of the cellular genome. BAF can
interact with double-stranded DNA in a sequence-independent
manner and homodimerizes to crossbridge and condense DNA
while forming higher order nucleoprotein complexes [42–45].
BAF also interacts with many cellular proteins including LAP2/
emerin/MAN1 (LEM) domain proteins that reside in the nuclear
envelope, histones, lamins, transcription factors, and DNA
damage response (DDR) proteins [46–51]. Using these interac-
tions, BAF is thought to act as a tethering protein to bring together
chromatin DNA and LEM proteins during late stages of mitosis
when the nuclear envelope (NE) is being reassembled. The
importance of BAF during mitosis is underscored by evidence that
misregulation of these BAF-dependent processes leads to chromo-
some segregation and NE defects, mislocalization of LEM
proteins, and embryonic lethality in Caenorhabditis elegans and
Drosophila melanogaster [52–55].
Interestingly, BAF is also a host defense effector against vaccinia
virus in the cytoplasm. Specifically, BAF is capable of inhibiting
vaccinia DNA replication [56] and transcription of vaccinia genes
[57]. This host defense activity of BAF depends on its DNA
binding and bridging properties and is blocked through phos-
phorylation by the vaccinia-encoded B1 protein kinase [58].
Phosphorylation of BAF by either the viral B1 or cellular protein
kinase VRK1 (vaccinia related kinase 1) strongly inhibits the
ability of BAF to bind DNA, thus regulating BAF-mediated
assembly of nucleoprotein complexes in both the cytoplasm and
nucleus [56,59,60]. Phosphorylation of BAF by both viral and
cellular kinases occurs at its N-terminus on Thr-2, Thr-3, and Ser-
4 [60,61]. While these sites are highly conserved throughout
evolution and regulate BAF in multiple organisms [62–64], much
remains to be learned about how they control the antiviral
capabilities of BAF.
Although BAF has antiviral activity directed against vaccinia, it
is not clear whether this activity is restricted to this poxvirus,
perhaps because its replication cycle occurs in the cytoplasm, or
whether it has antiviral activity directed against nuclear DNA
viruses as well. Consequently, we performed studies to examine
whether BAF has the potential to interfere with HSV-1 productive
infection. We found that HSV-1 infection led to the dephosphor-
ylation and rapid nuclear localization of BAF suggesting that it
sensed nuclear viral DNA. Interestingly, overexpression of a BAF
mutant that cannot be phosphorylated, the FLAG-BAF-MAAAQ
mutant, inhibited HSV-1 replication in mouse L929 cells as
compared to control cells or cells overexpressing epitope-tagged
wild type BAF. Relative to other viral proteins examined,
expression of VP16 and the ICP0 protein was strongly inhibited
in cells expressing the FLAG-BAF-MAAAQ mutant. These
experiments suggest that unphosphorylated BAF stably interacts
with nuclear HSV-1 DNA and interferes with productive infection
by impairing both viral DNA replication and gene expression.
Finally, these studies also suggest that phosphorylation of wild type
BAF down-regulates its antiviral function, thus allowing for
efficient HSV-1 replication.
Materials and Methods
Cell Culture
Mouse fibroblast L929 cells (obtained from the American Type
Culture Collection) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS; Atlanta Biologicals) and penicillin-streptomycin and
incubated at 37uC in a 5% CO2 atmosphere.
Mutagenesis and Cloning of BAF Mutants
To construct the vector for 1xFLAG-tagged BAF and 1xFLAG-
tagged BAF-MAAAQ, pcDNA5/FRT/TO/3XFLAG-BAF [56]
and pcDNA5/FRT/TO/3XFLAG-MAAAQ [58] were used as a
template for by PCR using outside primers Bam Kozak 1XFlag
(59-CTCGAGGGATCCGCCACCATGGATTACAAGGAT-
GACGATGAC-39) and BAF BamHI 39 (59-GCAGGATCCT-
CACAAGAAGGCGTCGCAC-39. PCR products were BamHI-
digested and ligated to BamHI-digested pHAGE-HYG-MCS
(pHM) lentiviral vector (a generous gift from Dr. Paula Traktman,
Medical College of Wisconsin) to generate pHM/HYG/1xFLAG-
BAF and pHM/HYG/1xFLAG-MAAAQ.
Production of Stably-expressing Cells
The stable overexpression of BAF in L929 cells was performed
by using a lentivirus expressing 1xFlag-BAF or BAF mutant as
previously described in Ibrahim et al., 2011. For transduction,
L929 cells were seeded in 35 mm dishes at ,16106 per well. The
next day, medium was replaced with 1 mL of lentivirus
supernatant for 24 h. Medium was then replaced with fresh
media for an additional 24 h. Cells were then passaged in media
containing 200 mg/ml of hygromycin to select for stable lentiviral
integration and a polyclonal population of cells was employed for
all experiments.
Virus Infections and Viral Yield Assay
A HSV-1 recombinant virus LAT-GFP, strain McKrae, and
Vaccinia (VACV) Cts2 virus were used for these studies. In
cultured cells, LAT-GFP grows like wt McKrae. All infections
were done at 37uC. For viral yield analysis, L929 cells (36106)
were infected with either virus at MOI= 0.01 for 48 h. For HSV-1
infection, following cell harvest, cells and media were collected and
frozen at 280uC. Samples were freeze-thawed three times
followed by centrifugation to pellet cell debris. Supernatant was
used for titration on Vero cells at 37uC. For vaccinia infection,
following cell harvest, cells were pelleted and suspended in 10 mM
Tris (pH 9). Samples were freeze-thawed three times prior to
titration on BSC40 at 32uC. For DNA replication analysis, L929
cells (36106) were infected with MOI= 0.1 for 3 h and 24 h.
Following cell harvest, cells were pelleted and DNA purified using
the GeneJET Whole Blood Genomic DNA Purification Mini Kit
(Thermo Scientific #K0782) prior to qPCR analysis. For
immunofluorescence analysis, L929 cells were infected with
MOI= 1 for 6 h. For western blot analysis, L929 cells were
infected with MOI= 1 for the indicated times prior to harvest.
Subcellular Fractionation
L929 cells (26106) were collected by scraping and washed in
PBS. Subcellular fractionations were performed as described in
(Wassler et al., 1987) with minor modification. Cell pellets were
BAF Can Act as a Host Defense Against HSV-1 Infection
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treated with cell lysis buffer (50 mM Tris-HCl pH 6.8, 2 mM
MgCl2, 150 mM NaCl, 0.5% saponin, protease inhibitor, and
phosphatase inhibitor) on ice for 10 min. Soluble fractions were
collected following centrifugation at 2000 rpm at 4uC for 10 min.
The insoluble pellets were further treated with Triton lysis buffer
(50 mM Tris-HCl pH 6.8, 2 mM MgCl2, 75 mM NaCl, 0.2%
Triton X-100, 0.1% SDS, protease inhibitors, and phosphatase
inhibitors) on ice for 10 min. TX-100 soluble fractions were
collected following centrifugation at 10,000 rpm at 4uC for
10 min. To each fraction, 2X protein sample buffer was added
followed by loading onto a 18% SDS-PAGE gel and electropho-
resis performed.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS) (10 mM Na2HPO4.7H2O, 1 mM KH2PO4, 2 mM
KCl, 140 mM NaCl, pH 7.4) at room temperature for 20 min.
Following fixation, cells were permeabilized with 0.2% Triton X-
100 in PBS for 10 min at room temperature. Cells were then
incubated with M2 FLAG antibody at a dilution of 1:300 for 1 h
at room temperature. Following washing with PBS, cells were then
incubated with Alexafluor 488-conjugated goat a-mouse-488
(Invitrogen) in PBS at 1:400 for 1 h at room temperature.
Fluorescence images were then taken by indirect fluorescence on
an inverted (Olympus IX 81) confocal microscope.
Immunoblotting Analysis
To examine protein expression in uninfected or infected cells,
L929 cells (16106) were harvested, pelleted, and suspended in
300 ml of SDS sample buffer (100 mM Tris pH 6.8, 2% b-
mercaptoethanol, 2% SDS, 32.5% glycerol, bromophenol blue)
supplemented with 10 units of Benzonase as described previously
[57]. Lysates were resolved on 18% SDS-PAGE gel when
analyzing BAF and resolved on 10% SDS-PAGE gel when
analyzing HSV-1 proteins. When examining protein expression
following infection of transduced cells, cells were washed 2X with
PBS and harvested in 300 mL RIPA buffer (50 mM Tris.HCl pH
8, 150 mM NaCl, 2 mM EDTA pH 8, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, and protease inhibitor). Cells were
disrupted by sonication for 20 sec and incubated at an end-to-end
rotator at 4uC for 30 min. Protein extracts were obtained
following centrifugation at 13,000 rpm at 4uC for 10 min. Protein
amount was quantified using Bradford assay and 50 mg lysate were
resolved on 10% SDS-PAGE gel. All protein was transferred to
PVDF membrane. Blots were then incubated with the appropriate
antibodies prior to signal development with chemiluminescent
reagents. Quantifications of the chemiluminescence signal were
performed by using Bio-Rad ChemiDocTM XRS instrument and
Bio-Rad ImageLabTM software. The primary antibodies used are
as follows: b-tubulin 1:20,000 (Sigma #T7816), FLAG M2
monoclonal 1:8000 (Sigma #F1804), BAF 1:5000 (custom
antibody [57]), phosphospecific BAF 1:1500 (custom antibody
[65]), ICP0 1:100 (Santa Cruz Biotechnology #sc-53070), ICP4
1:100 (Santa Cruz Biotechnology #sc-69809), ICP27 1:100 (Santa
Cruz Biotechnology #sc-17544), ICP8 1:100 (Santa Cruz
Biotechnology #sc-53329), TK 1:100 (Santa Cruz Biotechnology
#sc-28038), gD 1:100 (Santa Cruz Biotechnology #sc-21719),
and VP16 1:100 (Santa Cruz Biotechnology #sc-17547).
ChIP Assays
Chromatin immunoprecipitation was performed as described in
Ibrahim et al., 2013 [57] with the following minor modifications.
Cross-linking was performed with 0.75% PFA for 5 min. In
addition, after overnight incubation of lysates with antibodies and
a 2 h incubation with Dynabeads, beads were washed 3 times with
final wash buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM
EDTA pH 8, 1% Triton X-100, and 0.1% SDS) followed by
elution of bound complexes. Immunoprecipitated and input
material was analyzed by quantitative PCR (StepOne Plus Real
Time PCR, Applied Biosystems).
DNA/RNA Purification and qPCR
Viral DNA was extracted using GeneJET Whole Blood
Genomic DNA Purification Mini Kit (Thermo Scientific
#K0782) or QIAamp DNA Blood Mini Kit (Qiagen #51106).
For ChIP analysis, DNA was purified by glass bead purification
using Agarose Dissolving Buffer (Zymo Research #D4001-1-50).
qPCR was performed using SYBRHGreen PCR Master Mix
(Applied Biosystems #4309155 or Bio-Rad iTaq Universal
SYBRHGreen Supermix #172-5121). Serial dilutions were
included in each qPCR run to develop a standard curve and
determine the PCR efficiency of the primer sets in that experiment
set. qPCR analyses were performed using 1 mL of purified DNA
and 1 mM of each primers as followed: ICP0 R0 N1 (59-
AATGGGCAACCCCGGTATTC-39) and
ICP0 R0 N2 (59-GGAACCCCAGGGGAGTGGTTAC-39),
Actb-fwd-mouse (59-GGTCATCACTATTGGCAACG-39)
and
Actb-rev-mouse (59-CGTCACACTTCATGATGGAATTG-
39),
qpcrNEO-UP (59-CTTGCTCCTGCCGAGAAAGT-39) and
qpcrNEO-DOWN (59-TTCGCTTGGTGGTCGAATG-39).
Statistics
All experiments shown were performed in three or more
independent assays. Error bars shown in bar graphs represent
standard deviations from the mean. The p-values indicated were
calculated using the Student’s t-test. For western blot analyses, a
blot representative of at least three experiments is shown.
Results
HSV-1 Infection Induces Dephosphorylation of BAF
In this study we tested the hypothesis that BAF can impair the
lifecycle of a nuclear virus, HSV-1 for example, in a manner
regulated by phosphorylation and/or localization of BAF. For this
study, we have employed L929 cells because BAF possesses potent
anti-poxviral activity in this cell type, strongly impairing both
DNA replication and transcription of vaccinia genes when BAF is
not phosphorylated [57]. Building on previous data that
phosphorylation of BAF is altered during poxvirus infection, we
examined the effects that HSV-1 infection has on BAF phosphor-
ylation. For this study, antibodies specific to total BAF and
phosphorylated BAF were employed. As described previously,
BAF protein can be separated into two to three distinct protein
bands of approximately 10 kDa in size [56,59,60]. Each distinct
band detected by BAF-specific antibodies corresponds to specific
BAF phosphorylation states in which the protein migration
decreases as BAF becomes more phosphorylated. This property
of BAF allows us to monitor BAF phosphorylation using the ‘total
BAF’ antibody, which is able to recognize the fastest migrating
unphosphorylated form of BAF as well as two shifted phosphor-
ylated species. We also employ a phosphospecific BAF antibody,
which recognizes only the two post-translationally modified forms
of BAF due to the presence of one or more phosphate additions to
BAF. Expression of the viral immediate early protein ICP0 and
late protein VP16 were also monitored in this experiment as
indicators of progress through the viral lifecycle. As shown in
BAF Can Act as a Host Defense Against HSV-1 Infection
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Figure 1, there is a marked reduction in BAF phosphorylation
beginning at 6 hpi and continuing during all later time points. This
is indicated by the loss of the slowest migrating band detected by
the phosphospecific BAF antibody as well as the loss of the shifted,
phosphorylated form of BAF (gray arrowheads) and complemen-
tary increase in unphosphorylated BAF (black arrowhead) detected
by the total BAF antibody at 9 to 18 hpi. As expected ICP0 and
VP16 protein expression were not readily detected in mock-
infected cells. However, ICP0 was readily detected by 3 hours after
infection and VP16 was not detected until 6 hours after infection.
Similar levels of protein were loaded in each lane because tubulin
protein expression was detected in each lane. These data
demonstrate that HSV-1 infection triggers a decrease in steady
state levels of BAF phosphorylation.
Stable Expression of a Constitutively Unphosphorylated
Form of BAF in L929 Cells
To determine how dephosphorylated BAF may impact HSV-1,
we stably expressed epitope tagged versions of wild type BAF or a
BAF phosphorylation mutant in L929 cells. A FLAG epitope was
chosen because FLAG-BAF has been utilized in multiple studies
examining the phosphorylation of BAF, which have validated that
it is regulated by viral and cellular enzymes similarly to untagged
native BAF [56,60,61,63]. We have also found that in multiple cell
types, FLAG-BAF is localized to both the nucleus and cytoplasm,
and can inhibit DNA replication and gene transcription of
vaccinia virus in a manner dependent on the B1 kinase [56], thus
indicating that FLAG-BAF can be regulated through phosphor-
ylation as native BAF is. Specifically, to block BAF phosphory-
lation, we substituted the amino acids at known BAF phosphor-
ylation sites (Thr2, Thr3, and Ser4) to an alanine (A) (Figure 2A),
thus expressing a constitutively unphosphorylated form of BAF
(FLAG-BAF-MAAAQ), and have cloned the BAF sequence
encoding a wild-type N-terminus (MTTSQ) in the same vector
for comparison. Both constructs were expressed using a lentiviral
expression system, which allows for stable integration into the host
genome and hygromycin resistance. Following antibiotic selection
of transduced cells, expression of endogenous BAF and each
FLAG-BAF protein was verified by immunoblot analysis with an
anti-BAF antibody (Figure 2B). Consistent with these migration
patterns, the epitope-tagged BAF-MTTSQ and BAF-MAAAQ
also displayed distinct electrophophoretic mobilities reflecting the
amount of negatively changed amino acids at their N-terminus
regardless of whether the western blot was probed with the anti-
BAF or anti-FLAG antibody (Figure 2B and C). These results
confirm the stable expression of epitope tagged wild type and
mutant BAF in our L929 cells, with FLAG-BAF-MAAAQ
expressed at 20% of the level of FLAG-BAF-MTTSQ.
Phosphorylation Modulates the Subcellular Localization
of BAF in L929 Cells
Previous studies as well as our own recent data [65] indicate that
the subcellular localization and DNA binding activity of BAF can
depend on its phosphorylation state [60]. Therefore, we compared
the localization and DNA binding activity of FLAG-BAF-
MTTSQ and FLAG-BAF-MAAAQ in uninfected cells. We began
by analyzing the subcellular distribution of our stably expressed
proteins by an immunofluorescence assay using an anti-FLAG
antibody (Figure 3A). Like the native endogenous BAF [55,58,66–
68], FLAG-BAF-MTTSQ is expressed in the nucleus, nuclear
envelope and cytoplasm, and such localization is also consistent
with the published results on GFP-tagged and 3xFLAG-tagged
BAF [56,60,69,70]. With regard to the mutant BAF, we found
FLAG-BAF-MAAAQ primarily expressed in the nucleus. Next, to
complement our immunofluorescence analyses of these proteins,
we performed subcellular fractionation assays followed by
immunoblot analyses. First, cells were lysed with the pore-forming
agent saponin, which preferentially disrupts the plasma mem-
brane, followed by treatment of the saponin-insoluble fraction with
Triton X-100 and 0.1% SDS to complete disruption of the nuclear
membrane [71]. As expected, FLAG-BAF-MTTSQ was distrib-
Figure 1. HSV-1 infection induces dephosphorylation of BAF.
(A) Western blot analysis of cellular BAF and viral proteins upon
infection of L929 cells. Cells were infected with HSV-1 virus at MOI = 1
for the indicated times prior to harvest. Following cell harvest, protein
samples were resolved by SDS-PAGE and transfer to membrane.
Membranes were incubated with antibodies specific to the proteins
indicated at left. Data were obtained from three independent
experiments and representative blots are shown.
doi:10.1371/journal.pone.0100511.g001
Figure 2. Stable expression of BAF proteins in L929 cells. (A)
Point mutations were introduced to BAF N-terminal residues Thr2, Thr3,
or Ser4 as indicated in the amino acid alignment. In each case the
residue were mutated to A (alanine). (B–C) Representative western blot
analysis of whole cell lysates from cells stably-expressing BAF-MTTSQ
and BAF-MAAAQ. B) Anti-BAF antibody recognizes both endogenous
BAF protein (arrowheads) and FLAG-tagged proteins (bracketed). C)
Lysates from the same blot probed either withaGAPDH (top) or aFLAG
(bottom).
doi:10.1371/journal.pone.0100511.g002
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uted in both the saponin soluble (40%) and insoluble (60%)
fractions, consistent with its presence in both the cytoplasm and
nucleus (Figure 3B). In contrast, more than 95% of FLAG-BAF-
MAAAQ was present in the TX-100/SDS soluble nuclear
fraction, consistent with the immunofluorescence data above
finding that FLAG-BAF-MAAAQ is largely nuclear. Thus, these
results confirm and expand the evidence that BAF phosphoryla-
tion affect its subcellular distribution.
Based on previous evidence that BAF phosphorylation resulted
in reduced affinity for DNA in vitro [60], we hypothesized that
FLAG-BAF-MTTSQ may exhibit reduced DNA binding activity
in cells as compared to FLAG-BAF-MAAAQ. To test this, we
examined the DNA-binding activity of both proteins to either
genomic DNA or foreign DNA (plasmid) via chromatin immuno-
precipitation (ChIP) analysis. In this assay, L929 cells expressing
empty vector control, FLAG-BAF-MTTSQ or FLAG-BAF-
MAAAQ were transfected with 150 ng pUC-Neo plasmid for
24 h, and subsequently fixed with paraformaldehyde. Our recent
study demonstrated that transfected DNA co-precipitates with
FLAG-BAF-MTTSQ in ChIP analysis [57], validating plasmid as
a source of foreign DNA that can be bound by BAF. After harvest
and lysis of fixed cells, lysates were subjected to immunoprecip-
itation of FLAG-tagged BAF followed by reverse-crosslinking of
protein-DNA complex and qPCR analysis. qPCR was performed
on purified DNA by using primers specific for either the NeoR
gene or the b-actin locus, which was chosen to represent a region
of cellular chromatin. Fold enrichment was calculated relative to
our empty transduction vector control. From these analyses, we
found that FLAG-BAF-MTTSQ interacted with plasmid DNA
with an enrichment of ,14-fold (Figure 3C, left). FLAG-BAF-
MAAAQ interacts with plasmid DNA with a 13-fold enrichment,
similar to FLAG-BAF-MTTSQ. With respect to binding to
chromatin DNA, we found a similar trend of DNA binding
between the BAF proteins. Specifically, both FLAG-BAF-
MTTSQ and FLAG-BAF-MAAAQ were able to immunoprecip-
itate the b-actin locus with similar efficiency (Figure 3C, right). In
sum, these data show that in uninfected cells both FLAG-BAF-
MTTSQ and FLAG-BAF-MAAAQ immunoprecipitated similar
amounts of transfected or genomic DNA despite their different
subcellular localization. However, as we have not normalized for
the lower expression of FLAG-BAF-MAAAQ in these cells, we
may be underestimating the binding efficiency of FLAG-BAF-
MAAAQ using this approach.
HSV-1 Virus Production is Inhibited by
Unphosphorylatable BAF
Having observed that the phosphorylation of BAF is altered by
HSV-1, we sought to examine how this might affect BAF as well as
Figure 3. Subcellular distribution and DNA-binding activity of BAF mutants. (A) Immunofluorescence analyses of FLAG-BAF-MTTSQ and
FLAG-BAF-MAAAQ with an anti-FLAG antibody (AlexaFluor488-conjugated secondary antibody). (B) Subcellular fractionation analyses of cells
indicated in (A). Cell lysates were fractionated to saponin-soluble cytosolic fraction (grey bars) and insoluble nuclear fraction (black bars). Each
fraction was analyzed by western blot with an anti-FLAG antibody and quantified with ImageLab software (BioRad) (n = 3). % fraction was calculated
from the amount of protein on each fraction relative to the total protein level. Error bars represent standard deviations. (C) ChIP analyses of FLAG-
BAF-MTTSQ and BAF-MAAAQ. Cells were transfected with 150 ng of pUC-Neo plasmid DNA for 24 h followed by fixation, immunoprecipitation with
anti-FLAG antibody, and reverse crosslinking of protein-DNA complexes. Purified DNA was analyzed by qPCR using primers specific for the pUC-Neo
plasmid (Plasmid) or the b-actin locus of chromatin DNA (Genomic). Fold enrichment was obtained relative to empty vector control and normalized
to input DNA. Error bars represent standard deviations.
doi:10.1371/journal.pone.0100511.g003
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the viral lifecycle. We posited that either cellular pathways are
working to activate BAF’s antiviral DNA binding activity or
perhaps that the virus is actively triggering BAF dephosphorylation
to somehow enhance virus replication. First, we were interested in
whether the decrease in BAF phosphorylation we observed in
Figure 1 correlates with a change in its localization, as we saw with
FLAG-BAF-MAAAQ in Figure 3A. For these studies, examina-
tion of FLAG-BAF-MTTSQ localization was used because of the
greater sensitivity of the FLAG antibody in this assay. Indeed, by 6
hpi FLAG-BAF-MTTSQ clearly shifted to a more prominent
nuclear localization (Figure 4A). In contrast, FLAG-BAF-
MAAAQ is exclusively nuclear both in the presence and absence
of HSV-1, thus demonstrating that its localization remains
unchanged by infection. Together, these data provide the first
evidence that BAF becomes both dephosphorylated and re-
localized during the course of HSV-1 infection.
To test whether dephosphorylated BAF affects viral yield, we
infected FLAG-BAF-MAAAQ-expressing cells as well as control
and cells expressing FLAG-BAF-MTTSQ at a low MOI (0.01),
followed by harvesting intracellular virus at 48 hpi, and measuring
viral progeny by plaque titration assay. For comparison purposes,
parallel infections were performed on the same cell types with the
vaccinia Cts2 mutant virus, at the same MOI and time of harvest.
The Cts2 virus expresses a defective form of the vaccinia B1
kinase, making it highly sensitive to BAF because the virus is
unable to phospho-inactivate the antiviral activity of BAF
[56,72,73]. In regard to the HSV-1 infections, we found that the
amount of virus produced did not differ in cells overexpressing
FLAG-BAF-MTTSQ when compared to control cells (Figure 4B).
Strikingly however, in cells expressing the nuclear localized
unphosphorylated FLAG-BAF-MAAAQ protein, viral yield was
reduced more than 80%. As expected from our work in another
cell line [65], examination of Cts2 virus production in these cells
yielded the opposite results. Overexpression of the more cytoplas-
mic FLAG-BAF-MTTSQ decreased Cts2 viral yield ,80%, while
expression of FLAG-BAF-MAAAQ had no measurable impact on
Cts2 infection. Together, these data provide evidence that BAF is
clearly capable of host defense activity against vaccinia and it is
dephosphorylated and relocalized in the presence of HSV-1.
Furthermore, when BAF is not post-translationally modified at its
N-terminus, as in the FLAG-BAF-MAAAQ mutant, it can
interfere significantly with HSV-1 productive infection.
BAF Binds HSV-1 DNA and Impairs Viral DNA Replication
During infection with the Cts2 vaccinia virus, BAF binds to viral
DNA and interferes with viral DNA replication [56]. To test the
hypothesis that FLAG-BAF-MAAAQ may be acting through a
similar mechanism against HSV-1, we monitored viral DNA
accumulation in control cells and cells overexpressing FLAG-BAF-
MTTSQ and FLAG-BAF-MAAAQ (Figure 5A). Using real time
qPCR analysis, we determined that similar amounts of viral DNA
were present in all three cell types at 3 hpi. By 24 hpi, HSV-
1 DNA levels in control cells had increased 80-fold, and had
increased over 70-fold in cells expressing FLAG-BAF-MTTSQ.
However, viral DNA accumulation was inhibited greater than
75% in cells expressing FLAG-BAF-MAAAQ as compared to
controls. Next, we examined whether FLAG-BAF-MTTSQ or
FLAG-BAF-MAAAQ bind viral DNA during HSV-1 infection as
they do during vaccinia infection. Indeed, following FLAG-specific
chromatin immunoprecipitation we found that overexpression of
FLAG-BAF-MTTSQ led to an 8-fold enrichment of the ICP0
promoter as compared to control cells when measured by qPCR
(Figure 5B). Enrichment of viral DNA following immunoprecip-
itation of FLAG-BAF-MAAAQ was 20-fold, even greater that that
observed in FLAG-BAF-MTTSQ expressing cells, despite the fact
that FLAG-BAF-MAAAQ was expressed at lower levels (shown
earlier in Figure 1). Collectively, these data support our hypothesis
that BAF-MAAAQ impairs viral production, at least in part, by
binding to the viral genome more efficiently than BAF-MTTSQ,
thus leading to an impairment of genome replication.
BAF Impairs Expression of a Subset of Viral Proteins,
Including ICP0
In addition to inhibiting poxviral DNA replication, BAF is also
capable of repressing transcription from viral promoters during
infection with the Cts2 vaccinia virus [57]. To determine whether
HSV-1 gene expression may also be affected by FLAG-BAF-
MTTSQ or FLAG-BAF-MAAAQ, we performed western blot
analysis of viral proteins following infection of control cells or cells
expressing FLAG-BAF-MTTSQ or FLAG-BAF-MAAAQ. For
these studies, the designated L929 cells were infected with HSV-1
(MOI= 0.1) in three independent experiments. At 20 hours after
infection, the levels of viral proteins were examined by western
blot analysis and average differences in protein expression
calculated from those three assays. Seven viral proteins were
selected as representative examples of IE (ICP0, ICP4, ICP27), E
(ICP8, HSV-TK), and L (gD, VP16) genes (Figure 6). Following
infection of cells expressing FLAG-BAF-MAAAQ, there were
substantial changes in protein levels, with clear decreases in certain
members of all three kinetic classes. Most strikingly, the levels of
Figure 4. HSV-1 infection triggers relocalization of BAF to the
nucleus where unphosphorylatable BAF can suppress HSV-1
viral yield. (A) Immunofluorescence analyses of FLAG-BAF-MTTSQ or
MAAAQ cells infected with HSV-1 virus at MOI = 1 for 6 h. Following
fixation, cells were then stained with an anti-FLAG antibody (Alexa-
Fluor488-conjugated). (B) Viral yield analyses of HSV-1 and VACV Cts2-
infected cells. Indicated cell lines were infected with HSV-1 or VACV
Cts2 virus at MOI = 0.01 for 48 h at 37uC. Viral yield was calculated
relative to vector control for each infection (n = 3). Error bars represent
standard deviations (*indicates a p-value,0.05 from t-test analysis).
doi:10.1371/journal.pone.0100511.g004
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the E3 ubiquitin ligase/co-activator protein ICP0 were essentially
undetectable at 20 hours after infection. Furthermore, the co-
activator VP16, was present in FLAG-BAF-MAAAQ-expressing
cells at an average of only 12% (+/28% s.d.) of the level found in
control cells. Interestingly, there appeared to be differential
impacts of FLAG-BAF-MAAAQ on expression of specific genes.
For example, in contrast to ICP0 or VP16, expression of HSV-TK
and the transcriptional regulator ICP4 were largely unaffected,
while the ICP27, ICP8, and gD proteins were all reduced 55–
65%. By comparison, total cell lysate from FLAG-BAF-MTTSQ-
expressing cells contained equal or greater amounts of ICP4,
ICP27, ICP8, HSV-TK and gD, but contained only 70–80% of
the ICP0 and VP16 found in control cells. In sum, these data
argue that unphosphorylated BAF can inhibit the lifecycle of
HSV-1 in the nucleus by impairing both DNA replication and
expression of viral genes essential for productive infection.
Discussion
The DNA binding protein BAF has functions both in the
nucleus and the cytoplasm of the cell. In the nucleus, BAF
regulates nuclear reassembly in the late stages of mitosis [52–55].
Evidence can also be found for the involvement of BAF in
transcriptional regulation, transposon stabilization [74], and the
DNA damage response in the nucleus [47,49,75,76]. In the
cytoplasm, BAF can bind to foreign DNA and associates with
DNA of retroviral preintegration complexes, thereby protecting it
from undergoing suicidal autointegration in vitro [45,77,78]. The
ability of BAF to bind DNA in the cytoplasm also allows it to act as
Figure 5. Unphosphorylatable BAF mutant suppresses HSV-1
viral DNA replication and exhibits increased relative binding to
HSV-1 viral DNA. (A) Relative viral DNA accumulation of HSV-1-
infected FLAG-BAF-MTTSQ and MAAAQ cells. Cells were infected with
HSV-1 virus at MOI = 0.1 for 3 h and 24 h. Following harvest, cells were
analyzed for viral DNA accumulation via qPCR by using HSV-1 DNA-
specific primers. DNA accumulation was calculated relative to vector
control at 3 hpi (n = 3). Error bars represent standard deviations. (*
indicates a p-value,0.05 from t-test analysis) (B) ChIP analyses of viral
DNA bound to FLAG-BAF-MTTSQ and MAAAQ HSV-infected cells. Cells
were infected with HSV-1 virus at MOI = 1 for 6 h followed by fixation,
immunoprecipitation with anti-FLAG antibody, and reverse crosslinking
of protein-DNA complexes. Purified DNA was analyzed by qPCR using
primers specific for the ICP0 promoter region. Fold enrichment was
obtained relative to empty vector control and normalized to input DNA.
Data were obtained from three independent experiments performed in
triplicate wells and data from a representative experiment is shown.
Error bars represent standard deviations.
doi:10.1371/journal.pone.0100511.g005
Figure 6. Decreased HSV-1 viral protein expression can be
observed in unphosphorylatable BAF mutant cells. Western blot
analysis of HSV-1 viral proteins upon infection of FLAG-BAF-MTTSQ and
FLAG-BAF-MAAAQ cells. Cells were infected with HSV-1 virus at MOI = 1
for 20 h. Following cell harvest, protein samples were resolved by SDS-
PAGE and transfer to membrane. Membranes were incubated with
antibodies against HSV-1 proteins: ICP0, ICP4, ICP27, ICP8, TK, gD, and
VP16. Anti-tubulin antibody was used as a loading control. Data were
obtained from three independent experiments and a representative
blot is shown. Values represent average relative signal intensity from
three experiments as quantified by ImageLab software (BioRad).
doi:10.1371/journal.pone.0100511.g006
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a host defense against vaccinia infection. When BAF is hypo-
phosphorylated, it can localize to poxviral DNA [56] and impede
its replication in a manner dependent on the ability of BAF to
crossbridge DNA [58]. BAF also represses transcription from
vaccinia intermediate promoters; however, the ability of BAF to
impair poxviral DNA replication and transcription are blocked
through the action of the viral B1 kinase [56,57]. B1 is capable of
phosphorylating BAF, which inactivates the DNA binding activity
and antipoxviral capability of BAF. Despite its antiviral activity in
the cytoplasm, whether BAF is also capable of this function during
infection by a nuclear DNA virus has been unclear.
In addressing this question, we began with the premise that the
phosphorylation state of BAF could be affected by HSV-1
infection and may determine its antiviral activity in the nucleus,
as phosphorylation of BAF does in the cytoplasm against vaccinia
virus. Indeed, we observed that during HSV-1 infection, BAF
phosphorylation is sharply reduced. This decrease in phosphor-
ylation begins at 6 hpi and continues until almost no phosphor-
ylated BAF can be detected. Concomitant with dephosphoryla-
tion, we found BAF to relocalize to the nucleus, indicating that
BAF phosphorylation and localization are modulated during
HSV-1 infection as they are during vaccinia infection. To test how
BAF dephosphorylation might affect the viral lifecycle, we studied
not only epitope-tagged BAF-MTTSQ, but also an altered form of
the protein representing constitutively unphosphorylated BAF.
Analysis of the localization and DNA binding capabilities of these
proteins revealed that in uninfected cells the unphosphorylated
MAAAQ protein could bind DNA as efficiently as FLAG-BAF-
MTTSQ, but adopted a more nuclear localization. Similar results
using these mutants have also been obtained in primate cells [65],
demonstrating that phosphorylation regulates the localization of
BAF and its association with DNA across species.
Next, using cell lines expressing wild-type and unphosphory-
lated BAF, we performed HSV-1 infections and assayed the
production of new virus. We found that viral yield was consistently
reduced 80% in cells expressing FLAG-BAF-MAAAQ, providing
the first evidence suggesting that BAF can act as an inhibitor of
HSV-1 infection. In contrast, overexpression of FLAG-BAF-
MTTSQ had only a minor impact on viral yield (Figure 4B). To
verify that our FLAG-BAF-MTTSQ clone is capable of antiviral
activity, we also compared viral yields from the same three cell
lines following infection with the vaccinia Cts2 virus. This mutant
virus was employed because it lacks expression of an active form of
the B1 kinase [72,73], which we previously demonstrated was
required to inactivate BAF via direct phosphorylation. Measure-
ment of Cts2 viral progeny from these cell lines demonstrated an
80% reduction in yields in cells expressing FLAG-BAF-MTTSQ,
but not cells expressing FLAG-BAF-MAAAQ. This result
demonstrated that the MAAAQ mutant, which was localized
primarily to the nucleus, was unable to localize to the cytoplasm
even though vaccinia replication and transcription was occurring
in the cytoplasm.
We found the reciprocal abilities of FLAG-BAF-MTTSQ and
MAAAQ to impair HSV-1 versus Cts2 vaccinia virus intriguing
for the following reasons. First, the fact that FLAG-BAF-MAAAQ
can bind DNA, but does not inhibit vaccinia suggests that
phospho-regulation of the localization of BAF is crucial for its anti-
viral activity against that virus. Second, in regard to HSV-1, it is
possible that the increased presence of FLAG-BAF-MAAAQ in
the nucleus may enhance its antiviral activity against nuclear
viruses, in general. An additional possibility is that since FLAG-
BAF-MTTSQ can be phosphorylated at its N-terminus, it may
have reduced activity against HSV-1 because it is modified by a
cellular and/or viral kinase. If this kinase activity is ongoing during
the course of infection it would antagonize dephosphorylation of
BAF, thus delaying the antiviral activity of BAF past a point in the
viral lifecycle when it is most effective. One example of a cellular
nuclear kinase specific for BAF is known; the cellular Vaccinia
Related Kinase 1 has significant homology to the vaccinia B1
kinase [79] and plays an important role in phosphorylating BAF
during mitosis [63,69]. Further studies are needed to determine
whether VRK1 or other cellular/viral kinases are regulators of the
antiviral activity of native BAF or FLAG-BAF-MTTSQ in the
nucleus.
Upon discovering that FLAG-BAF-MAAAQ expression corre-
lates with reduced HSV-1 yield, we hypothesized that the
mechanism of action might be similar to the antipoxviral activity
of BAF. Specifically, we have previously published evidence that
BAF can bind to vaccinia DNA and impair both DNA replication
and transcription from viral promoters [57,58]. The data
presented herein are fully consistent with this hypothesis.
Specifically, BAF does bind to HSV-1 DNA as measured by
ChIP assay, and the reduced accumulation of replicated viral
DNA in MAAAQ-expressing cells suggests that HSV-1 DNA
replication was impaired. The finding that expression of the c2 L
viral protein VP16 was inhibited in infected cells expressing
unphosphorylatable BAF is consistent with reduced viral DNA
replication because it is well established that c2 L gene expression
occurs after viral DNA replication [80]. Conversely, inhibition of
gD protein expression in L929 cells expressing the FLAG-BAF-
MAAAQ mutant is not merely the result of reducing viral DNA
replication because HSV-1 gD is a prototype c1 gene that is
expressed early during infection and its expression is not
dramatically altered by a viral inhibitor of DNA replication,
phosphonoacetic acid for example [80]. Furthermore, reduction of
viral DNA replication would not explain the finding that
expression of the immediate early protein ICP0 was not observed
under the conditions of these studies in L929 cells expressing the
FLAG-BAF-MAAAQ mutant. Conversely, expression of ICP4,
another IE transcriptional regulator was not dramatically reduced
following infection of L929 cells that express the FLAG-BAF-
MAAAQ mutant adding credence to our conclusion that the
FLAG-BAF-MAAAQ mutant did not have the same result on
expression of all viral proteins. Relative to other HSV-1 promoters
(IE, E, or L), the full-length ICP0 promoter is long and contains
binding sites for numerous cellular transcription factors [81–83]
suggesting BAF may preferentially interact with one or more of
these cellular factors to inactivate the ICP0 promoter. Since the
ICP0 promoter also contains 10 VP16/Oct1 binding sites, a
dramatic reduction in VP16, as seen in L929 cells expressing the
FLAG-BAF-MAAAQ mutant, may also reduce ICP0 expression.
Studies to test these predictions are in progress.
In sum, these data demonstrate for the first time that the
antiviral activity of BAF is not exclusive to vaccinia in the
cytoplasm, but can also be observed in the nucleus in a
phosphorylation-dependent manner. Together with other recently
published evidence, our studies support a model in which mitotic
regulation or cellular stresses including viral infection or other
insults [84] modulate BAF via phosphorylation. In that regard, it
will be of interest to determine whether overlap exists between
mitotic and stress signaling cascades upstream of BAF. For
example, the VRK1-PP2A/PP4 signaling axis known to target
BAF during mitosis [62,85] may also be involved in the
dephosphosphorylation of BAF we observed in this study.
Additionally, since HSV-1 encodes two serine/threonine protein
kinases (US3 and UL13) [86–88], it is not unreasonable to suggest
that one of these viral encoded protein kinases directly or
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indirectly plays a role in maintaining BAF phosphorylation to help
keep it disarmed during infection.
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